NB-UVB for Systemic Inflammation

About Cytokind

Founded in 2018 and based in San Diego, Cytokind is pivoting from its initial cell therapy focus to commercialize prescription NB-UVB light therapy devices for home-based treatment of autoimmune and inflammatory conditions. The company positions its technology as a non-pharmacologic intervention to calm systemic inflammation, supported by translational research in areas like MS fatigue and post-COVID recovery. Led by a team with medical device and biotech experience, Cytokind operates a direct-to-patient model requiring a physician's prescription, aiming to expand the application of a well-established dermatological treatment into broader immunology.

Therapeutic Areas